Fig. 5

The tumor growth blockade effects by the cotreatment of FAK inhibition and PLD are related to antitumor immunity. A-F Treatment evaluation for the combination of IN10018 and PLD on CT26 models generated in BALB/c nude mice. IN10018 was dosed at 12.5 mg/kg through oral gavage once daily. PLD was dosed at 1.5 mg/kg by teil vein injection once weekly (n = 3 per group). G-L The treatment evaluation of the combination of IN10018 and PLD within the CT26 model generated in BALB/c mice. The treatment schedules are the same as (A-F) (n = 3 per group). M-R The peritoneal tumor sizes indicated by the bioluminescence signals and body weight records from the mouse ovarian cancer peritoneal model ID8-Luc. The model was treated for 35 days. After then, extensive observation was performed for another 2 weeks (n = 5 per group). Data represent mean ± SEM. Statistical analysis was done using one-way ANOVA. NS means non-significant. *P < 0.05